{"id":"intramuscular-olanzapine-aripiprazole","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Sedation"},{"rate":"10-30","effect":"Weight gain"},{"rate":"5-15","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"10-20","effect":"Metabolic syndrome"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, while aripiprazole acts as a dopamine D2 partial agonist and serotonin 5-HT1A partial agonist. The intramuscular formulation provides rapid onset and sustained therapeutic levels, making it suitable for acute agitation or maintenance treatment in patients with schizophrenia, bipolar disorder, or other psychotic disorders.","oneSentence":"Olanzapine and aripiprazole are atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and agitation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:50.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute agitation or maintenance)"},{"name":"Acute agitation in psychotic disorders"}]},"trialDetails":[{"nctId":"NCT00895921","phase":"PHASE4","title":"Examining the Effects of Antipsychotic Medications on Insulin Sensitivity","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2008-11","conditions":"Diabetes","enrollment":30},{"nctId":"NCT01411930","phase":"PHASE4","title":"Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2009-03","conditions":"Diabetes","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olanzapine -> Aripiprazole"],"phase":"marketed","status":"active","brandName":"Intramuscular olanzapine, aripiprazole","genericName":"Intramuscular olanzapine, aripiprazole","companyName":"Veterans Medical Research Foundation","companyId":"veterans-medical-research-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine and aripiprazole are atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and agitation. Used for Schizophrenia, Bipolar disorder (acute agitation or maintenance), Acute agitation in psychotic disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}